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Purpose: Low grade inflammation is a well-known characteristic in obese sub-
jects. We investigated body weight changes and inflammatory markers after 12-
week intervention trial. Materials and Methods: Twenty-six obese subjects were 
enrolled and 19 (13 men and 6 women) completed the study. Sibutramine is an 
FDA-approved drug for body weight control; therefore, we chose this drug as the 
standard treatment medication in this study. Patients were randomly allocated to re-
ceive an anti-inflammatory agent (Diacerein treatment group; n = 12) or placebo (n 
= 7) for 12 weeks. Anthropometry, body proportion by dual-energy X-ray absorpti-
ometry, and metabolic parameters at the beginning and end of study were measured 
and compared. Results: The treatment group had a tendency towards more reduc-
tion in anthropometry as compared to the placebo group, in body weight reduction 
(- 7.0 kg vs. - 4.6 kg), body mass index (- 2.51 kg/m2 vs. - 1.59 kg/m2), and waist 
circumference (- 7.3 cm vs. - 4.4 cm). These reductions were not statistically signif-
icant. Changes in levels of high-sensitivity C-reactive protein and adiponectin in 
the treatment group were more favorable than in the placebo group. Conclusion: 
This small pilot study showed no statistical difference for changes in anthropome-
try, and inflammatory markers between the two groups. Therefore, we could not 
find any additional effects of Diacerein on weight loss and inflammatory variables 
in this study. 
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INTRODUCTION
In Korea, the third National Health and Nutrition Survey in 2005 reported that the 
overall prevalence of adult obesity [defined as a body mass index (BMI) ≥ 25.0 
kg/m2] was 31.7% (35.2% in men and 28.3% in women),1 which represents an in-
crease from corresponding Figs. in 2001 (overall 29.6%, 31.2% in men and 27.9% 
in women). In Korea and elsewhere, obesity is a concern, as it heightens the risk of 
developing hypertension, diabetes, dyslipidemia, and cancers, and can cause pre-Anti-Inflammatory Agent and Body Weight
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take treatment medication (Diacerein) or placebo for 12 
weeks. All subjects were enrolled following a private inter-
view conducted at the Obesity Clinic of Ajou University 
Hospital, Suwon, South Korea, and all provided informed 
consent. We measured and compared the anthropometric 
changes of body weight and waist circumference), body pro-
portion using Dual Energy X-ray Absorptiometry (DEXA), 
select metabolic parameters, and inflammatory markers be-
fore and after the 12-week body weight control program. 
The Institutional Review Board of Ajou University Hospi-
tal approved this study, and permission was received from 
the Korean Food and Drug Administration for the use of 
Diacerein. 
Inclusion criteria for the initial 26 obese subjects were 
age ≥ 20-years-of-age, BMI ≥ 27.0 kg/m2, or 27 kg/m2 ≥ 
BMI ≥ 25.0 kg/m2 with hypertension, type 2 diabetes, dys-
lipidemia, and family history of coronary heart diseases. 
Exclusion criteria were uncontrolled type 2 diabetes, hyper-
tension, habitual alcohol consumption, history and/or cur-
rent presence of any cancer, old stroke, and renal disease. 
Seven subjects dropped out due to personal problems that 
were unrelated to an adverse drug reaction. The remaining 
19 subjects (13 men, 6 women) completed the study. 
Weight reduction program and visit schedules
Subjects visited an out-patient clinic every 4 weeks for a 
meeting with the principal investigator and the coordinating 
nurse. At each visit, each subject was assessed and prompted 
to continue their prescribed routine. Items addressed at each 
visit included information on diet, daily activity, types and 
frequency of exercise, encouragement, and advice concern-
ing target frequency of exercise (at least 30 min daily, more 
than 3 or 4 times a week). Each subject underwent an initial 
nutrition assessment by a registered dietician, who provided 
instructions on a low-calorie diet aimed at producing a 400-
500 kcal daily energy deficit. Furthermore, a behavior modi-
fication program encouraged increased calorie expenditure 
while reducing intake, with an emphasis on long-term behav-
ior change. In addition, Sibutramine was prescribed as a stan-
dard medical treatment for all subjects. Subjects were ran-
domly assigned in a double-blind manner to the treatment 
group (n = 12) who additionally received the anti-inflamma-
tory agent Diacerein, which is a TNF-α inhibitor, and to the 
placebo group (n = 7). Diacerein and placebo were made and 
provided by Myungmoon Pharmaceutical (Seoul, Korea). 
The capsules were identical in appearance; the placebo con-
tained wheat flour instead of medication. 
mature death.2
The increase in fat mass, particularly in the splanchnic re-
gion (visceral fat) of the body, is associated with chronic el-
evation of circulating levels of inflammatory mediators, in-
cluding non-specific markers such as C-reactive protein 
(CRP), acute-phase inflammatory proteins, and proinflam-
matory cytokines.3,4 The relationship between obesity, in-
flammatory markers such as adipocytokines, phase reactant 
proteins, and insulin resistance has been investigated in 
several populations.5,6 Reviews on low grade inflammation 
have presented evidence indicating that the reversion of 
low grade inflammation and reduction of risk factors in 
obese individuals seems to coincide with reduced BMI and 
loss of adipose tissue.7 Reduced body weight could result in 
normalized inflammation and reduction in increased in-
flammatory markers. Even a modest 5-10% loss of body 
weight in obese patients improves their cardiovascular risk 
profiles and reduces the future incidence of type 2 diabe-
tes.8-10 Therefore, weight reduction is a key factor in reducing 
inflammation and thus the risk of cardiovascular disease. 
Diacerein is well-tolerated anti-inflammatory supplemen-
tal agent, which acts by inhibiting tumor necrosis factor-al-
phas (TNF-α) and interleukin-1 (IL-1) in rheumatoid and 
other forms of arthritis. This compound has also been used 
to reduce inflammation in addition to more conventional 
anti-inflammatory drugs.11-14 Furthermore, only two studies 
have addressed whether pharmacological intervention15-17 
reduces inflammation.
Diacerein is an anti-inflammatory agent, which is often 
used in some clinical-based office of the obesity clinic in Ko-
rea. From a clinical view standpoint, obesity is equivalent to a 
status of low-grade inflammation; therefore, reduction of in-
flammation may lead to a change in body weight. However, 
there have been no reports of Diacerein effects on body weight 
control. Therefore, we wondered if this medication had any 
real effect on body weight control or inflammatory marker 
changes. The aim of this study was to evaluate the additional 
effect on body weight reduction, metabolic parameters, and 
inflammatory markers by addition of an anti-inflammatory 
agent to a standard 12-week obesity treatment regimen. 
MATERIALS AND METHODS
Study subjects
We conducted a double-blind, placebo-controlled pilot 
study. Enrolled obese subjects were randomly allocated to Nam-Seok Joo, et al.
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tionally, all of the subjects underwent blood tests [standard 
enzymatic measurements of total cholesterol, high-density 
lipoprotein cholesterol, triglycerides and fasting glucose, in-
sulin, high-sensitivity C-reactive protein (hsCRP), homocys-
teine, fibrinogen, and other metabolic parameters in fresh se-
rum samples] at the beginning and end of the 12-week 
program. All blood measurements were done using a model 
TBA-200FR apparatus (Toshiba, Tokyo, Japan). TNF-α was 
measured using a Quantikine Human TNF-α enzyme im-
mune assay (EIA)(R&D Systems, Minneapolis, MN, USA). 
Adiponectin was measured using a human adiponectin ra-
dioimmunoassay (RIA) kit (R&D Systems). We also ana-
lyzed changes in intake of macronutrients using a three-day 
recall food diary by the CAN-Pro 3.0 nutrition analyzer 
(Korean Nutrition Society, Seoul, Korea).
Measurements
A research nurse measured the height and body weight of 
the participants while they were wearing light clothing and 
no shoes. Their weight was measured to the nearest 0.1 kg, 
and height was measured to the nearest centimeter. BMI 
was calculated as the weight divided by height squared (kg/
m2). The nurse also measured the waist circumference be-
tween the lower rib and the iliac crest, electrically measured 
blood pressure using a model TM-2655P apparatus (PMS 
Instruments, Tokyo, Japan) after the participants had been 
at rest for at least 15 min, and checked each subject’s nutri-
tional status every 4 weeks by inspection of a food diary 
kept by each participant. The body composition of each 
participant was analyzed by DEXA using a IDXA series 
(LUNAR apparatus GE, Schenectady, NY, USA). Addi-
Table 1. Baseline Characteristics of the Two Groups 
Treatment (n = 12) Placebo (n = 7) p value
Age (yrs) 39 ± 1 37 ± 1 0.299
Height (cm) 167 ± 2 171 ± 3 0.340
Weight (kg) 87 ± 4 89 ± 3 0.482
BMI (kg/m
2) 31 ± 1 30 ± 1 0.592
Waist (cm) 99 ± 2 99 ± 3 0.837
FFM (kg) 52 ± 2 53 ± 1 1.000
FM (kg) 31 ± 2 32 ± 3 0.650
F%M (kg) 37 ± 2 37 ± 2 0.902
s-BP (mmHg) 125 ± 3 121 ± 4 0.650
d-BP (mmHg) 78 ± 3 78 ± 4 0.902
Glucose (mg/dL) 108 ± 7 100 ± 2 0.902
HDLC (mg/dL) 46 ± 1 45 ± 4 0.650
LDLC (mg/dL) 120 ± 13 109 ± 12 0.837
TG (mg/dL) 186 ± 49 140 ± 25 0.902
TC (mg/dL) 203 ± 14 194 ± 9 0.837
TSH (μIU/mL)   1.8 ± 0.2   1.7 ± 0.2 0.902
Insulin (μU/μL ) 16 ± 2 19 ± 4 0.650
HOMA-IR    4.5 ± 1.0   4.7 ± 1.1 0.773
WBC count (× 10
3/μL)   7.0 ± 0.5   7.1 ± 0.6 0.967
HsCRP (mg/dL)   1.21 ± 0.94   0.45 ± 0.09 0.261
Homocysteine (mg/dL) 11.1 ± 0.6 12.7 ± 0.5 0.340
Fibrinogen (mg/dL) 376.7 ± 14.0 367.5 ± 28.9 0.773
TNF-α (pg/mL) 15.7 ± 1.4 11.5 ± 2.7 0.227
Adiponectin (μg/mL)   6.2 ± 0.7   6.7 ± 1.1 0.773
BMI, body mass index; Waist, waist circumference; FFM, fat free mass; FM, fat mass; F%M, fat mass Percentage in body; s-BP, systolic 
blood pressure; d-BP, diastolic blood pressure; Glucose, fasting glucose; HDLC, high-density lipoprotein cholesterol; LDLC, low-density 
lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; TSH, thyroid stimulating hormone; HOMA-IR, homestasis Model Assess-
ment of Insulin Resistance; WBC, white blood cells; hsCRP, highly-sensitive C-reactive protein; TNF-α, tumor necrosis factor-α. 
p values from Mann-Whitney U test.
All data are expressed as mean±standard error; p values from Mann-Whitney U test comparing changes between the two groups. Anti-Inflammatory Agent and Body Weight
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RESULTS
After random allocation according to age, BMI, 19 of 26 
subjects (73%) completed the study. Twelve subjects (7 men 
and 5 women) were in the treatment group and seven sub-
jects (6 men and 1 woman) were in the placebo group. The 
mean age was 39.58 ± 1.42 years in the treatment group and 
Statistical analyses
This study sample size was small, so we used non-paramet-
ric comparison (Mann-Whitney U test) to see the difference 
between the two groups. We used an χ2 test to evaluate the 
rates of over 5% and 10% weight reduction between the 
two groups. All significant values were defined by p < 0.05 
as determined by SPSS version 11.5 (SPSS, Chicago, IL, 
USA). 
Table 2. Comparisons of Anthropometry, Calorie Intake and Metabolic Changes between the Two Groups for 12 Weeks
Variable Treatment (n = 12) Placebo (n = 7) p value
   Δ Bwt (kg)   - 7.0 ± 0.9*   - 4.6 ± 1.2* 0.167
   Δ BMI (kg/m
2)   - 2.5 ± 0.3*   - 1.5 ± 0.4* 0.120
   Δ Wc (cm)   - 7.3 ± 1.9*   - 4.4 ± 1.0* 0.340
   Δ FM (kg)   - 4.1 ± 0.7*   - 3.1 ± 0.7* 0.335
   Δ F%M (%)   - 2.4 ± 0.4*   - 2.0 ± 0.5* 0.616
   Δ FFM (kg)   - 1.9 ± 0.6*   - 1.4 ± 0.6* 0.682
   Δ s-BP (mmHg) - 8.7 ± 4.6 - 1.7 ± 3.7 0.340
   Δ d-BP (mmHg) - 5.1 ± 4.7 - 0.7 ± 5.2 0.482
   Δ Glucose (mg/dL) 10.2 ± 3.3   4.2 ± 4.6 0.650
   Δ TC (mg/dL) - 22.6 ± 18.6 - 8.4 ± 6.2 0.773
   Δ HDLC (mg/dL)   7.4 ± 6.2   5.2 ± 1.7 0.837
   Δ LDLC (mg/dL)  - 12.8 ± 7.2*   3.1 ± 9.3 0.261
   Δ TG (mg/dL)   164.5 ± 191.3 - 29.4 ± 16.9 0.711
   Δ Insulin (μU/μL ) - 1.5 ± 2.0  -7.9 ± 3.8 0.261
   Δ HOMA-IR - 0.16 ± 0.82 - 1.73 ± 0.82 0.261
   Δ Caloriestotal (kcal) - 178.3 ± 93.3 - 113.5 ± 89.7 0.964
   Δ Carbohydrate (g)  - 1.0 ± 1.8   4.3 ± 1.9 0.083
   Δ Fat (g)  - 1.9 ± 2.0 - 2.1 ± 1.1 0.750
   Δ Protein (g)    2.1 ± 1.1 - 0.3 ± 2.1 0.213
Δ, amount of change; BMI, body mass index; FM, fat mass; F%M, fat mass Percentage in body; FFM, fat free mass; s-BP, systolic blood 
pressure; d-BP, diastolic blood pressure; Glucose, fasting glucose; TC, total cholesterol; HDLC, high-density lipoprotein cholesterol; 
LDLC, low-density lipoprotein cholesterol; TG, triglyceride; TSH, thyroid stimulating hormone; ΔCaloriestotal, change in total calorie in-
take; ΔCarbohydrate, change in carbohydrate intake; ΔFat, change in fat intake; ΔProtein, amount of protein intake changes.
All data are expressed as mean ± standard error; p values from Mann-Whitney U test comparing changes between the two groups. 
*p < 0.05 by paired t test before and after the changes of each parameter in the same groups. 
Table 3. Comparisons of Changes in Inflammatory Markers between the Two Groups for 12 Weeks
Variable Treatment (n = 12) Placebo (n = 7) p value
   Δ WBC (×10
3/μL) 0.03 ± 0.45   0.02 ± 0.35 0.482
   Δ hsCRP (mg/dL)  - 0.86 ± 0.86* - 0.21 ± 0.10 0.227
   Δ Homocysteine (mg/dL) 3.84 ± 2.25   1.98 ± 1.29 0.902
   Δ Fibrinogen (mg/dL) 25.16 ± 11.46   12.57 ± 25.01 0.773
   Δ TNF-α (pg/mL) - 5.37 ± 2.56 - 6.20 ± 3.23 0.837
   Δ Adiponectin (μg/mL)   0.72 ± 0.63* - 0.45 ± 0.53 0.227
Δ, amount of change; WBC, white blood cell; hsCRP, high-sensitivity C-reactive protein; TNF-α, tumor necrosis factor-α.
All data are expressed mean ± standard error.
p values from Mann-Whitney U test.
*p < 0.05 by paired t test before and after the changes of each parameter in the same groups. Nam-Seok Joo, et al.
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the two groups, in spite of the small sample size. Both re-
sponse rates were higher in the treatment group than in the 
placebo group. Even though there were no statistical differ-
ences between the two groups, P for trend showed weak cor-
relation in more weight reduction tendency in the treatment 
group than in the placebo group (Fig. 1). In spite of these re-
sults, we could not find any additional effects of Diacerein on 
weight loss and inflammatory variables in this study.
DISCUSSION
In this pilot study, we did not find any additional effects of 
Diacerein on weight loss and inflammatory variables. As 
mentioned above, two-way ANOVA may not be useful in 
this study. Therefore, we had only simple comparison by 
non-parametric test. The treatment group as compared to 
the placebo group showed a reduction in body weight (- 7.0 
kg vs. 4.6 kg), BMI (- 2.51 kg/m2 vs. - 1.59 kg/m2), and 
waist circumference (- 7.3 cm vs. - 4.4 cm); however, there 
was no statistical significance between the two groups. 
Changes in levels of low-density lipoprotein, hsCRP, and 
adiponectin in the treatment group showed improvement, 
which were also not significant when compared to those in 
the placebo group. Other inflammatory markers such as 
white blood cells, homocysteine, fibrinogen, and TNF-α 
were not significantly different either. 
There have been many studies of changes of the inflam-
mation and body weight in several different body weight 
control programs. For instance, studies on the changes in 
inflammatory markers after weight reduction reported dif-
ferent results, which may have reflected the different study 
methods. One study showed that during the eucaloric 
phase, a low-fat, high-carbohydrate diet unfavorably influ-
37.57 ± 1.11 in the placebo group, and the mean BMI was 
31.02 ± 1.08 kg/m2 in the treatment group and 30.51 ± 1.94 
kg/m2 in the placebo group. Besides the anthropometric mea-
surements, other metabolic parameters [blood pressure, fast-
ing blood sugar, lipid profiles, thyroid stimulating hormone, 
insulin, and homeostasis model assessment-Insulin Resis-
tance (IR)], and several inflammatory markers including 
white blood cell count, hsCRP, homocysteine, fibrinogen, 
TNF-α, and adiponectin level were also measured; no differ-
ences between the two groups were evident (Table 1). We 
had difficulty mentioning the two-way ANOVA test because 
we did not divide the time-dependent grouping. We only 
measured body composition and inflammatory markers at 
baseline and 12 weeks. Following the 12-week weight reduc-
tion program the mean changes in body weight, BMI, and 
waist circumference were - 7.00 kg, - 2.51 kg/m2, and - 7.37 
cm, respectively, in the treatment group, and - 4.64 kg, - 1.59 
kg/m2, and - 4.42 cm, respectively, in the placebo group. The 
anthropometric comparison before and after intervention 
showed significant changes in both groups. A tendency to-
wards more reduction in anthropometric parameters in the 
treatment group was observed, but there was no statistical 
difference between the two groups. In addition, there were 
no statistical differences in the changes of metabolic param-
eters and calorie intake between the treatment and control 
groups (Table 2). We also evaluated the changes in inflam-
matory markers between the two groups. Again, no statisti-
cal differences were apparent. Although there were no dif-
ferences between the two groups, hsCRP, and adiponectin 
showed more favorable change in the treatment group than 
in the placebo group. Other inflammatory markers were not 
shown as expected, but TNF-α was decreased in both groups 
after intervention (Table 3). Finally, we observed the re-
sponse rate of ≥ 5% and ≥ 10% weight reduction between 
Fig. 1. Response rate: weight reduction of ≥ 5% and ≥10% in the two groups. The top panel shows the response rate of ≥ 5% or < 5% 
weight reduction subjects after the 12-week intervention. The lower panel shows the response rate of ≥ 10% or < 10% weight reduction.
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personal reasons. Furthermore, the relatively short duration 
of this intervention would contribute to the lack of change 
in inflammatory markers, as in previous studies. Another 
limitation is that the intervention medication we used (Dia-
cerein, an anti-inflammatory agent that is a TNF-α and IL-1 
inhibitor) is not an officially recognized agent in the regula-
tion of inflammation in the obese. Additionally, we could 
not evaluate total exercise time and frequency, which are 
important confounding factors. Nonetheless, to our knowl-
edge, this is the first randomized, placebo-controlled study 
that investigated the effect of inclusion of an anti-inflamma-
tory agent to a traditional obesity control regimen involving 
medication with Sibutramine, to evaluate whether there 
was additional reduction of weight and of inflammatory 
markers. In conclusion, we did not find any additional ef-
fects of Diacerein on weight loss and inflammatory vari-
ables in this study.
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